查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1985524

无血清培养基市场：按产品类型、无血清培养基类型、细胞类型、配方、应用和最终用户划分－2026-2030年全球市场预测

Serum-Free Media Market by Product Type, Serum-Free Media Type, Cell Type, Formulation, Application, End User - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年无血清培养基市场价值为 25.1 亿美元，预计到 2025 年将成长至 27.6 亿美元，复合年增长率为 10.07%，到 2030 年将达到 44.7 亿美元。

主要市场统计数据
基准年 2024 25.1亿美元
预计年份：2025年 27.6亿美元
预测年份 2030 44.7亿美元
复合年增长率 (%) 10.07%

这篇富有洞察力的介绍将无血清培养基定位为可重复细胞培养、可扩展生物製程和更安全的生物製药开发的基础。

随着科学进步、监管要求和商业性需求不断重塑科研和生产环境中的细胞培养技术，无血清培养基的格局也迅速演变。无血清培养基已从小众技术解决方案发展成为基础技术，能够降低变异性、减轻生物风险并简化下游製程。相关人员优先考虑成分明确、性能可重复以及与可扩展生物製程流程的兼容性，以支援更先进的生物製药、细胞和基因治疗以及再生医学应用。

科学进步、监管监督和细胞疗法的产业化正在将无血清培养基转变为策略性的生物工艺推动因素。

在科学创新、细胞疗法产业化以及监管机构对原材料可追溯性日益重视的推动下，无血清培养基领域正经历着一场变革。细胞株工程和系统生物学的进步推动了对特定细胞表型定製製剂的需求，使得培养基的配方从标准化转向能够优化生产效率和关键品质属性的客製化。同时，细胞和基因疗法的产业化也增加了对能够在大规模生产环境中稳定运行，并能满足监管机构对成分一致且特性明确的原材料的要求的培养基的需求。

评估关税中断对无血清培养基原料和物流对下游供应链和营运韧性的影响。

2025年公布的关税政策的累积影响，为原料和无血清配方产品的供应链带来了新的复杂性。影响试剂、胺基酸、特殊生长因子和包装组件的关税措施，可能导致关键原料的接收成本增加和交货前置作业时间延长。为应对此问题，采购和供应链团队正在优先考虑库存策略、替代采购管道和供应商认证活动，以确保供应的连续性，同时维持产品品质和合规性。

全面的细分洞察揭示了细胞类型、产品结构、培养基成分选择、应用要求和最终用户需求如何塑造培养基成分策略。

细分市场为解读无血清培养基生态系中技术需求与商业性机会的交会点提供了一个系统性的观点。基于细胞类型，区分哺乳动物细胞和非哺乳动物细胞对于配方设计至关重要，因为它们在营养利用效率、生长动力学和产品品质特性方面存在显着差异。哺乳动物细胞，例如 CHO 细胞、HEK293 细胞、NS0 细胞和 Vero 细胞，在渗透压、生长因子和添加剂方面表现出不同的需求，这些需求会影响细胞生产力和转译后修饰。非哺乳动物细胞，以昆虫细胞和酵母细胞为代表，具有不同的代谢需求和耐受性，通常需要不同的缓衝液和碳源策略，同时兼顾成本效益。

决定全球部署模式、供应链策略和发展重点的区域趋势和监管环境。

区域趋势显着影响无血清培养基在不同生态系的开发、生产与应用。在美洲，学术创新中心、合约研发生产力机构 (CDMO) 和大规模生物製药生产设施之间的紧密合作，推动了对符合 GMP 标准且具备可扩展生产流程的製剂的需求。此外，该地区的管理体制和成熟的供应链网路也支持从实验室到临床实践的快速转化。

在无血清培养基生态系统中，塑造产品创新、伙伴关係和品质主导差异化的竞争和企业策略。

无血清培养基领域的竞争格局由那些兼具配方专业知识、法规知识和供应链能力的公司所主导。主要企业正投资研发特定应用培养基，推出针对高价值治疗领域的产品，并拓展分析服务以支援客户的合格评估。与合约研发生产机构 (CDMO) 和学术研究中心建立策略伙伴关係十分普遍，这有助于加速专业配方的检验和市场推广进程。

为研发、供应链、监管和商业领域的领导者提供实用建议，以增强韧性、加速推广应用并提高产品与市场的契合度。

为实现策略价值，产业领导者应采取一系列合作倡议，将研发、供应链和商业部门连结起来。首先，应优先投资分析平台和细胞特异性製剂科学，以加速开发週期并降低规模化生产过程中的风险。同样重要的是製定灵活的生产策略，包括关键原材料的双重采购和区域生产方案，以减轻政策和物流方面的影响。

严谨且多方面的调查方法，结合专家访谈、技术文献和相关人员检验，确保了可靠且可操作的见解。

本研究途径整合了定性专家访谈、技术文献彙编以及与研发、生产和采购等相关相关人员的直接对话，从而对无血清培养基的现状提供多角度的观点。资料收集包括与配方科学家、製程开发经理和采购专家进行结构化访谈，以及查阅同行评审文章、监管指南和企业资讯披露，以阐明产品特性和验证途径。

全面概述了无血清培养基在现代细胞培养和生物製药开发中作为策略性、稳健且应用主导部分的地位。

总之，无血清培养基正从一项技术基础发展成为一项策略性资产，影响研发速度、产品品质和生产稳定性。细胞生物学和分析技术的进步使得更精细的配方成为可能，以满足哺乳动物和非哺乳动物系统的多样化需求。同时，配方和产品类型的选择旨在平衡操作便利性和法规的清晰度。监管要求和区域生产能力的差异正在影响无血清培养基的推广应用，而不断变化的贸易政策则促使企业考虑加强供应链并在适当情况下实现本地化生产。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：无血清培养基市场：依产品类型划分

  • 自订培养基
  • 预定义培养基

第九章：无血清培养基市场－以无血清培养基类型划分

  • 化学成分明确的培养基（CDM）
  • 通用无血清培养基（SFM）
  • 非动物源性（NAO）培养基
  • 无蛋白培养基（PFM）
  • 不含异质成分的培养基

第十章 依细胞类型分類的无血清培养基市场

  • 哺乳动物细胞
    • CHO细胞
      • CHO-DG44
      • CHO-DXB11
      • CHO-K1
    • HEK293
    • NS0细胞
    • Vero细胞
  • 非哺乳动物细胞
    • 昆虫细胞
    • 酵母菌细胞

第十一章 无血清培养基的市场剂型

  • 液体类型
  • 粉末型

第十二章：无血清培养基市场：依应用领域划分

  • 学术研究
    • 基因编辑
    • 干细胞研究
  • 生物製药生产
    • 单株抗体
    • 重组蛋白
    • 疫苗
  • 细胞和基因治疗
    • CAR-T疗法
    • 干细胞疗法
  • 组织工程与再生医学

第十三章 无血清培养基市场：依最终用户划分

  • 生技公司
  • 合约研究机构
  • 製药公司

第十四章 无血清培养基市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 无血清培养基市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 无血清培养基市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国无血清培养基市场

第十八章：中国无血清培养基市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Ajinomoto Co., Inc.
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Corning Incorporated
  • Danahar Corporation
  • FUJIFILM Holdings Corporation
  • Lonza Group AG
  • Merck KGaA
  • MP Biomedicals, LLC
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-7C31448F0BA9

The Serum-Free Media Market was valued at USD 2.51 billion in 2024 and is projected to grow to USD 2.76 billion in 2025, with a CAGR of 10.07%, reaching USD 4.47 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.51 billion
Estimated Year [2025] USD 2.76 billion
Forecast Year [2030] USD 4.47 billion
CAGR (%) 10.07%

An insightful introduction that frames serum-free media as a cornerstone enabling reproducible cell culture, scalable bioprocessing, and safer biologics development

The serum-free media landscape is evolving rapidly as scientific advances, regulatory expectations, and commercial imperatives converge to reshape how cell culture is performed across research and production environments. Serum-free formulations have transitioned from niche technical solutions to foundational enabling technologies that reduce variability, mitigate biological risks, and streamline downstream processing. Industry stakeholders are prioritizing defined inputs, reproducible performance, and compatibility with scalable bioprocessing workflows in order to support higher-complexity biologics, cell and gene therapies, and regenerative medicine applications.

Technological progress in media chemistry, analytical characterization, and cell biology has expanded the functional footprint of serum-free solutions. This progress is underpinned by increased understanding of cell-specific nutrient requirements, novel supplement strategies that replace poorly defined serum components, and a stronger emphasis on quality control across raw materials. Consequently, organizations that align formulation design with cell biology and manufacturing constraints can improve process consistency and reduce regulatory friction. As a result, serum-free media are now evaluated not only for biological performance but also for supply-chain robustness and compatibility with single-use systems, automation, and closed processing to meet contemporary production needs.

How scientific advancements, regulatory scrutiny, and industrialization of cell therapies are reshaping serum-free media into a strategic bioprocess enabler

The landscape for serum-free media is undergoing transformative shifts driven by scientific innovation, industrialization of cell therapies, and heightened regulatory attention to raw material traceability. Advances in cell-line engineering and systems biology have increased demand for formulations tailored to specific cellular phenotypes, moving away from one-size-fits-all recipes toward bespoke media that optimize productivity and critical quality attributes. Concurrently, the industrialization of cell and gene therapies has created pressure for media that perform robustly at scale while supporting regulatory dossiers that require consistent, well-characterized inputs.

In addition, sustainability and supply-chain resilience are rising priorities. Manufacturers are targeting reduction of animal-derived components to address ethical concerns and reduce variability, while procurement teams are adopting multi-sourcing strategies to guard against disruptions. Analytical innovations, including improved metabolite profiling and real-time process monitoring, enable more precise formulation tuning and faster troubleshooting of process drift. Taken together, these shifts are accelerating the maturation of serum-free media from a specialized reagent into a strategic component of bioprocess platforms that supports reproducibility, regulatory compliance, and operational scalability.

Evaluating the downstream supply chain and operational resilience consequences stemming from tariff-driven disruptions affecting serum-free media inputs and logistics

The cumulative impact of tariff policies announced for 2025 has introduced new complexity into supply chains for raw materials and finished serum-free formulations. Tariff measures affecting reagents, amino acids, specialized growth factors, and packaging components have the potential to increase landed costs and extend lead times for critical inputs. In response, procurement and supply chain teams are prioritizing inventory strategies, alternative sourcing, and supplier qualification activities to maintain continuity of supply while preserving product quality and compliance.

Beyond immediate cost pressures, tariffs influence strategic location decisions for manufacturing and fill-finish operations. Some organizations are reassessing regional sourcing hubs and considering nearshoring to reduce exposure to tariff volatility and transport disruptions. Regulatory compliance considerations remain paramount, as any supply-chain realignment must preserve documentation for traceability and change control. As a consequence, companies are investing in enhanced supplier audits, dual-sourcing where feasible, and tighter contractual protections to manage risk. Collectively, these responses underscore a broader trend toward resilient supply architectures designed to absorb policy-driven shocks while maintaining the performance and safety that end-users expect.

Comprehensive segmentation insights revealing how cell type, product architecture, formulation choices, application demands, and end-user needs shape formulation strategies

Segmentation provides a structured lens to interpret where technical demand and commercial opportunity intersect within the serum-free media ecosystem. Based on cell type, distinctions between Mammalian Cells and Non-Mammalian Cells are central to formulation design because nutrient utilization, growth kinetics, and product quality attributes differ markedly. Mammalian Cells, including CHO Cells, HEK293, NS0 Cells, and Vero Cells, present diverse requirements for osmolality, growth factors, and supplements that influence productivity and post-translational modifications. Non-Mammalian Cells, exemplified by Insect Cells and Yeast Cells, impose different metabolic demands and tolerance profiles, often enabling cost efficiencies but requiring alternative buffering and carbon source strategies.

Based on product type, differentiation between Custom Media and Defined Media drives procurement and R&D priorities. Custom Media solutions are tailored for specific cell lines or product goals and often require deeper analytical support and iterative optimization, whereas Defined Media prioritize reproducibility and regulatory clarity by minimizing undefined components. Based on formulation, choices between Liquid Form and Powdered Form have operational implications: liquid formats deliver convenience and reduced reconstitution variability but involve higher transport volumes and cold-chain considerations, while powdered formats offer storage and logistics advantages alongside on-site reconstitution needs.

Based on application, academic research, biopharmaceutical production, cell & gene therapy, and tissue engineering each demand unique performance attributes. Academic Research applications, including Gene Editing and Stem Cell Research, value flexibility and experimental reproducibility. Biopharmaceutical Production subsegments-Monoclonal Antibodies, Recombinant Proteins, and Vaccines-prioritize process consistency, scalability, and regulatory documentation. Cell & Gene Therapy areas such as CAR-T Therapy and Stem Cell Therapy require media that support cell viability, functionality, and safety in clinical manufacturing. Finally, based on end user, requirements differ across Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, with each class placing distinct emphasis on speed-to-data, regulatory readiness, and scalable supply.

Regional dynamics and regulatory landscapes that determine adoption patterns, supply-chain strategies, and development priorities across global regions

Regional dynamics significantly influence how serum-free media are developed, produced, and adopted across different ecosystems. The Americas exhibit strong integration between academic innovation hubs, contract development and manufacturing organizations, and large-scale biopharmaceutical production facilities, which together drive demand for formulations that are compatible with GMP environments and scalable manufacturing workflows. Regulatory systems and established supply-chain networks in this region also support rapid translation from lab to clinic.

Europe, Middle East & Africa blends stringent regulatory oversight with a diverse supplier base and growing investment in advanced therapies. In this region, emphasis on traceability, ethical sourcing, and compliance with complex regulatory frameworks encourages adoption of highly characterized, defined formulations. The need for harmonized documentation and environmental sustainability considerations also shapes procurement decisions.

Asia-Pacific combines accelerating biopharmaceutical development with manufacturing capacity expansion and rapidly evolving regulatory frameworks. Local demand for cost-effective and high-performance media is rising in parallel with investments in indigenous cell therapy programs and vaccine production. Moreover, partnerships between multinational firms and regional manufacturers are influencing formulation availability and local qualification processes. Across all regions, strategic considerations such as supply-chain localization, regulatory harmonization, and talent development remain central to successful deployment of serum-free solutions.

Competitive and corporate strategies shaping product innovation, partnerships, and quality-driven differentiation in the serum-free media ecosystem

Competitive dynamics in the serum-free media space are shaped by companies that combine formulation expertise, regulatory know-how, and supply-chain capabilities. Leading organizations are investing in application-specific media, launching products that target high-value therapeutic segments, and expanding analytical services to support customer qualification. Strategic partnerships with contract development and manufacturing organizations and academic centers of excellence are common, enabling faster validation and route-to-market for specialized formulations.

Innovation pathways include modular product architectures that enable rapid customization, licensing models that facilitate co-development, and service offerings that bundle technical support, method transfer, and stability data. In parallel, manufacturers are placing emphasis on raw material traceability and supplier transparency to meet the heightened expectations of regulatory agencies and forward-looking customers. Companies that integrate robust quality management systems with agile commercial and technical support functions are positioned to win in environments where performance, documentation, and continuity of supply converge as decisive buyer criteria.

Practical recommendations for R&D, supply chain, regulatory, and commercial leaders to build resilience, accelerate adoption, and improve product-market fit

To capture strategic value, industry leaders should adopt a set of coordinated actions that align R&D, supply chain, and commercial functions. First, prioritize investments in analytical platforms and cell-specific formulation science to accelerate development cycles and reduce risk during scale-up. Equally important is the development of flexible manufacturing strategies that include dual sourcing for critical inputs and options for regional production to mitigate policy and logistics disruptions.

Next, reinforce regulatory and quality frameworks by documenting raw material provenance, implementing comprehensive supplier qualification programs, and maintaining robust change control processes to expedite regulatory submissions. From a commercial perspective, offer tiered product and service packages that address the distinct needs of academic labs, CDMOs, and pharmaceutical manufacturers, thereby improving customer retention and enabling premium service offerings. Finally, foster collaborative ecosystems with academic centers and clinical partners to validate formulations in relevant applications, create shared data assets, and accelerate adoption across translational pathways. Together, these measures increase resilience, improve product-market fit, and support sustainable growth.

A rigorous, multi-source research methodology combining expert interviews, technical literature, and stakeholder validation to ensure reliable and actionable insights

The research approach integrates qualitative expert interviews, technical literature synthesis, and primary engagement with stakeholders across R&D, manufacturing, and procurement to produce a nuanced perspective on the serum-free media landscape. Data collection included structured conversations with formulation scientists, process development leaders, and procurement specialists, complemented by review of peer-reviewed publications, regulatory guidance, and company disclosures that clarify product attributes and validation pathways.

Analytical methods emphasized triangulation to ensure findings reflect operational realities: cross-validation of technical performance claims with independent laboratory reports, comparison of supplier capabilities against documented quality systems, and mapping of application requirements to formulation characteristics. For segmentation and regional analysis, the methodology relied on direct input from end users and service providers to identify demand drivers and operational constraints. Throughout, the research adhered to rigorous standards for source attribution, methodological transparency, and reproducibility so readers can evaluate the alignment of insights with their own data and priorities.

Concluding synthesis that emphasizes serum-free media as a strategic, resilient, and application-driven component of modern cell culture and biologics development

In summary, serum-free media are transitioning from technical enablers to strategic assets that influence development speed, product quality, and manufacturing resilience. Scientific advances in cell biology and analytics are enabling more tailored formulations that meet the diverse needs of mammalian and non-mammalian systems, while formulation formats and product types are being selected to balance operational convenience with regulatory clarity. Regional differences in regulatory expectations and manufacturing capacity shape adoption trajectories, and evolving trade policies are prompting companies to shore up supply chains and consider localization where appropriate.

Moving forward, organizations that invest in application-specific R&D, strengthen supplier transparency, and align commercial models to end-user needs will be best positioned to deliver value. Integration of high-quality analytical data with collaborative partnerships will accelerate qualification and adoption, and careful attention to operational resilience will mitigate the impact of policy and logistics disruptions. Collectively, these elements point to a future where serum-free media are integral to reproducible science and scalable biologics manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Serum-Free Media Market, by Product Type

  • 8.1. Custom Media
  • 8.2. Defined Media

9. Serum-Free Media Market, by Serum-Free Media Type

  • 9.1. Chemically Defined Media (CDM)
  • 9.2. Common Serum-Free Media (SFM)
  • 9.3. Non-Animal Origin (NAO) Media
  • 9.4. Protein-Free Media (PFM)
  • 9.5. Xeno-Free Media

10. Serum-Free Media Market, by Cell Type

  • 10.1. Mammalian Cells
    • 10.1.1. CHO Cells
      • 10.1.1.1. CHO-DG44
      • 10.1.1.2. CHO-DXB11
      • 10.1.1.3. CHO-K1
    • 10.1.2. HEK293
    • 10.1.3. NS0 Cells
    • 10.1.4. Vero Cells
  • 10.2. Non-Mammalian Cells
    • 10.2.1. Insect Cells
    • 10.2.2. Yeast Cells

11. Serum-Free Media Market, by Formulation

  • 11.1. Liquid Form
  • 11.2. Powdered Form

12. Serum-Free Media Market, by Application

  • 12.1. Academic Research
    • 12.1.1. Gene Editing
    • 12.1.2. Stem Cell Research
  • 12.2. Biopharmaceutical Production
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Recombinant Proteins
    • 12.2.3. Vaccines
  • 12.3. Cell & Gene Therapy
    • 12.3.1. CAR-T Therapy
    • 12.3.2. Stem Cell Therapy
  • 12.4. Tissue Engineering & Regenerative Medicine

13. Serum-Free Media Market, by End User

  • 13.1. Biotechnology Companies
  • 13.2. Contract Research Organizations
  • 13.3. Pharmaceutical Companies

14. Serum-Free Media Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Serum-Free Media Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Serum-Free Media Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Serum-Free Media Market

18. China Serum-Free Media Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Ajinomoto Co., Inc.
  • 19.6. Becton, Dickinson and Company
  • 19.7. Bio-Techne Corporation
  • 19.8. Corning Incorporated
  • 19.9. Danahar Corporation
  • 19.10. FUJIFILM Holdings Corporation
  • 19.11. Lonza Group AG
  • 19.12. Merck KGaA
  • 19.13. MP Biomedicals, LLC
  • 19.14. Sartorius AG
  • 19.15. STEMCELL Technologies Canada Inc.
  • 19.16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL SERUM-FREE MEDIA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL SERUM-FREE MEDIA MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CUSTOM MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY DEFINED MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHEMICALLY DEFINED MEDIA (CDM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COMMON SERUM-FREE MEDIA (SFM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-ANIMAL ORIGIN (NAO) MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PROTEIN-FREE MEDIA (PFM), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY XENO-FREE MEDIA, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DG44, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-DXB11, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CHO-K1, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY HEK293, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NS0 CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VERO CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY INSECT CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY YEAST CELLS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY LIQUID FORM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY POWDERED FORM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL RESEARCH, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 118. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 122. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 123. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 124. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 125. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 127. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 128. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. AMERICAS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 135. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 136. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 137. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 140. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. NORTH AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 148. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 149. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 150. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 153. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 154. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. LATIN AMERICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 187. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 188. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 189. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 190. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 192. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 193. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. MIDDLE EAST SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 196. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 200. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 201. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 202. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 203. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 205. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 206. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. AFRICA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 222. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 227. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 228. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 229. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 230. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 232. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 233. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. ASEAN SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. GCC SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 236. GCC SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GCC SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. GCC SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. GCC SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 240. GCC SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 241. GCC SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 242. GCC SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. GCC SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. GCC SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 245. GCC SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 246. GCC SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. GCC SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 259. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPEAN UNION SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. BRICS SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 262. BRICS SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. BRICS SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. BRICS SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 266. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 267. BRICS SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 268. BRICS SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 269. BRICS SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. BRICS SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 271. BRICS SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 272. BRICS SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 273. BRICS SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. G7 SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 275. G7 SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. G7 SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. G7 SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. G7 SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 279. G7 SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 280. G7 SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 281. G7 SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 282. G7 SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. G7 SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 284. G7 SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 285. G7 SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 286. G7 SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. NATO SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 288. NATO SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. NATO SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NATO SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. NATO SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 292. NATO SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 293. NATO SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 294. NATO SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. NATO SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. NATO SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 297. NATO SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 298. NATO SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. NATO SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. GLOBAL SERUM-FREE MEDIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 302. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 306. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 307. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 308. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 309. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 311. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 312. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED STATES SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. CHINA SERUM-FREE MEDIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 315. CHINA SERUM-FREE MEDIA MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. CHINA SERUM-FREE MEDIA MARKET SIZE, BY SERUM-FREE MEDIA TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CELL TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. CHINA SERUM-FREE MEDIA MARKET SIZE, BY MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 319. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CHO CELLS, 2018-2030 (USD MILLION)
  • TABLE 320. CHINA SERUM-FREE MEDIA MARKET SIZE, BY NON-MAMMALIAN CELLS, 2018-2030 (USD MILLION)
  • TABLE 321. CHINA SERUM-FREE MEDIA MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 322. CHINA SERUM-FREE MEDIA MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. CHINA SERUM-FREE MEDIA MARKET SIZE, BY ACADEMIC RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 324. CHINA SERUM-FREE MEDIA MARKET SIZE, BY BIOPHARMACEUTICAL PRODUCTION, 2018-2030 (USD MILLION)
  • TABLE 325. CHINA SERUM-FREE MEDIA MARKET SIZE, BY CELL & GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 326. CHINA SERUM-FREE MEDIA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)